Skip to content
Research Article Open access CC BY 4.0

Pharmacological and Therapeutic Features of COVID - 19 Infection in Hodeidah, Yemen

Mohammed Amood Al-Kamarany, Hussien Omer Alkadi, Mohammed Yahia Almadani, Zainulbedeen Ali Alsharma, Rashad Mohammed Al-Salehy, Nabil Ahmed Albaser

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 18–36 · Published 23 Mar 2024

10.9734/jamps/2024/v26i5683

Abstract

Background: The symptoms and signs of coronavirus diseases 2019 (COVID-19) present at illness onset vary, but over the course of the disease, most persons with COVID-19 will experience the following: fever, cough, fatigue, anorexia, shortness of breath, hypoxia, sputum production, and myalgia. During the first year (2020), there was no effective cure for COVID-19 infection and the most common treatment for patients was supportive therapy. Ministry of Public Health and Population in Yemen presented national guideline that is extracted from other countries and World Health Organization (WHO). Objective: Therefore, in this research, we discuss the pharmacological and therapeutic approaches for management of COVID-19 during its early period of rampage, using availability of medicines in Yemeni local pharmaceutical marketing. On the other hand, the efficacy of therapeutic  was monitored. Methodology: 505 patients with COVID-19 from Hodeidah showed that respiratory infection illness can range from mild to critical. Mild to moderate was 386 case (78.93 %), severe cases was 73 cases (15.13 %) and critical cases was 28 cases (5.93 %). The major criteria for cases admission namely clinical examination, case definition, clinical investigation, radiological finding, hematological and biochemical finding and molecular biology assay namely real – time - polymerase chain reaction (RT- PCR). The pharmacological and therapeutic properties of supportive therapy of COVID-19 included" antipyretic agent, antiviral (oseltamivir) analgesic agent, glucocorticoid (dexamethasone), anticoagulant agent (enoxaparin), anti-cough (acetylcysteine), antibiotics broad spectrum to treat the secondary infection namely azithromycin, ceftriaxone, ceftazidime,  piperacillin and tazobactam, meropenam, and moxifloxacin. In addition, oxygen therapy is the major treatment that used in treatment of severe and critical cases. Also, vitamins (C and D) and mineral namely zinc were prescribed and proton pump inhibitor (PPI) (pantaprazol), anti-emetic (Ondansetron). Fluid therapy namely ringer lactate or normal saline were used in management of COVID -19. Results: The results showed that the age of the patients included in this study between 3- 92 years with 4.0 to 1.0 males: females.  49 patients were admitted in COVID-19 isolation department of Hodeidah, Yemen. 25/49 cases (54.34% ) were recovered with national guideline,  the average of  RR  pre - treatment was 30 ± 5 breath / minute and reduced to  23 ± 2 breath / minute post – treatment with significantly statistically different (p < 0.05). On the other hand, the clinical symptoms namely difficult in breathing, cough, fever, and headache reduced to absent absolutely (100 %). In addition, the results showed that the average of WBC pre - treatment was 20 ± 4 (×109/L) and reduced to 7 ± 2 (×109/L) post – treatment with significantly statistically different (p < 0.05). Also, lymphocytes decreased with COVID -19 infection to 2 % with average (10±5%) and improved post - treatment to 20 %.  In addition, neutrophil increased to 95 % with average (80±15%) and improved to 70 % post-treatment. the average of WBC pre - treatment was 20 ± 4 (×109/L) and reduced to 7 ± 2 (×109/L) post-treatment with significantly statistically different (p < 0.05). The outcome finding of management that 19 cases (3.88 %) of severe and 6 cases (1.22 %) of critical were recovered. On the other hand, 1 case of severe and 21 cases of critical COVID-19 were died. Conclusion: In spite of lack of specific antiviral drugs, the approach of pharmacology and therapeutics had good impact at level of mild to moderate cases, and severe cases while the critical cases needs to develop at level critical cases in intensive care unit (ICU) with mechanical ventilation (MV) procedure.

COVID-19 pharmacology therapeutic Hodeidah Yemen

References (37)

  1. 1 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  2. 2 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  3. 3 The psychological impact of quarantine and how to reduce it: rapid review of the evidence [DOI]
  4. 4 Dexamethasone in Hospitalized Patients with Covid-19 [DOI]
  5. 5 Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China [DOI]
  6. 6 Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study [DOI]
  7. 7 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  8. 8 A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy [DOI]
  9. 9 Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial [DOI]
  10. 10 Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [DOI]
  11. 11 Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) [DOI]
  12. 12 Basic and Clinical Pharmacology [DOI]
  13. 13 Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action [DOI]
  14. 14 Mode of Action of Fluoroquinolones [DOI]
  15. 15 Acute pain management: scientific evidence, fourth edition, 2015 [DOI]
  16. 16 Verification and quality control of routine hematology analyzers [DOI]
  17. 17 Pharmacology of Opioids in the Treatment of Chronic Pain Syndromes [DOI]
  18. 18 Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis [DOI]
  19. 19 Pharmacological treatment of COVID-19: an opinion paper [DOI]
  20. 20 Co-circulation of Dengue and Chikungunya Viruses, Al Hudaydah, Yemen, 2012 [DOI]
  21. 21 Chikungunya outbreak in Al-Hudaydah, Yemen, 2011: Epidemiological characterization and key lessons learned for early detection and control [DOI]
  22. 22 COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns [DOI]
  23. 23 Dengue Fever Infection in Hodeidah, Yemen: Risk Factors and Socioeconomic Indicators
  24. 24 Detection of Dengue Fever Virus Serotype – 4 by using One-Step Real-Time RT-PCR in Hodeidah, Yemen [DOI]
  25. 25 Epidemiological Characteristic of Malaria Coinfected with Dengue Fever in Hodeidah, Yemen [DOI]
  26. 26 Epidemiological and Clinical Features of COVID-19 in Hodeidah, Yemen [DOI]
  27. 27 Radiological Features of COVID-19 Patients in Hodeidah, Yemen [DOI]
  28. 28 Outbreak Investigation: First Ten COVID – 19 Infection Related Deaths in Hodeidah, Yemen [DOI]
  29. 29 Hematological and Coagulation Features of COVID-19 Patients in Hodeidah, Yemen [DOI]
  30. 30 Validation Hematological Analyzer for Assay of Erythrogram in Hodeidah City, Yemen
  31. 31 Biomolecular Features of COVID-19 in Hodeidah, Yemen [DOI]
  32. 32 Coronavirus Disease 2019 – Dengue Fever Coinfection: A Case Report [DOI]
  33. 33 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
  34. 34 Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report [DOI]
  35. 35 Coronavirus breakthrough: dexamethasone is first drug shown to save lives [DOI]
  36. 36 International Journal of Laboratory Hematology [DOI]
  37. 37 The novel coronavirus disease (COVID-19) outbreak trends in mainland China: a joinpoint regression analysis of the outbreak data from January 10 to February 11, 2020 [DOI]

Cited by 1

IMPACT MONITORING OF LOW AND HIGH DEXAMETHASONE DOSES ON COVID-19 OUTCOMES IN HODEIDAH, YEMEN: A PHARMACOEPIDEMIOLOGICAL STUDY

MOHAMMED AMOOD AL KAMARANY, ABDULLAH H MADD, ALI AHMED MOHAJAB · Asian Journal of Pharmaceutical and Clinical Research · 2025

Related research

Article metrics

Real usage data collected on this platform.

42

Page views

0

PDF downloads

4

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.